(Q35909593)

English

Antineoplastic agents. 515. Synthesis of human cancer cell growth inhibitors derived from 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene

scientific article published in August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Antineoplastic agents. 515. Synthesis of human cancer cell growth inhibitors derived from 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene (English)

1 reference

Europe PubMed Central

11 August 2017

1 reference

based on heuristic

inferred from title

George R. Pettit

1

object named as

George R Pettit

1 reference

Europe PubMed Central

11 August 2017

author name string

Collin R Anderson

2

1 reference

Europe PubMed Central

11 August 2017

Eric J Gapud

3

1 reference

Europe PubMed Central

11 August 2017

M Katherine Jung

4

1 reference

Europe PubMed Central

11 August 2017

John C Knight

5

1 reference

Europe PubMed Central

11 August 2017

Ernest Hamel

6

1 reference

Europe PubMed Central

11 August 2017

Robin K Pettit

7

1 reference

Europe PubMed Central

11 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 August 2005

1 reference

Europe PubMed Central

11 August 2017

Journal of Natural Products

1 reference

Europe PubMed Central

11 August 2017

68

1 reference

Europe PubMed Central

11 August 2017

8

1 reference

Europe PubMed Central

11 August 2017

1191-1197

1 reference

Europe PubMed Central

11 August 2017

Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

27 July 2018

Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

27 July 2018

Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

27 July 2018

(3-Amino-2-oxoalkyl)phosphonic acids and their analogues as novel inhibitors of D-alanine:D-alanine ligase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

27 July 2018

New colorimetric cytotoxicity assay for anticancer-drug screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

27 July 2018

Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

27 July 2018

Antineoplastic agents. 487. Synthesis and biological evaluation of the antineoplastic agent 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene and derived amino acid amides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Antineoplastic agents 460. Synthesis of combretastatin A-2 prodrugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Combination bacteriolytic therapy for the treatment of experimental tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate prodrugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Antineoplastic agents 365. Dolastatin 10 SAR probes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Guanosine 5'-O-(3-thiotriphosphate), a potent nucleotide inhibitor of microtubule assembly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335365

24 September 2018

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16124759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin

1 reference

https://pubmed.ncbi.nlm.nih.gov/16124759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain

1 reference

https://pubmed.ncbi.nlm.nih.gov/16124759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/16124759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications

1 reference

https://pubmed.ncbi.nlm.nih.gov/16124759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16124759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16124759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/16124759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16124759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1021/NP058033L

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35909593&oldid=2165542659"